These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24396690)

  • 1. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus.
    Cho YM; Wideman RD; Kieffer TJ
    Endocrinol Metab (Seoul); 2013 Dec; 28(4):262-74. PubMed ID: 24396690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014; 143 Suppl 2():12-7. PubMed ID: 25326838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity.
    Maselli DB; Camilleri M
    Adv Exp Med Biol; 2021; 1307():171-192. PubMed ID: 32077010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
    Baggio LL; Drucker DJ
    Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials.
    Gilbert MP; Pratley RE
    Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
    Lund A; Knop FK; Vilsbøll T
    Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
    Fineman MS; Cirincione BB; Maggs D; Diamant M
    Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ
    Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing incretin action for the treatment of type 2 diabetes.
    Drucker DJ
    Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretins: a new treatment option for type 2 diabetes?
    Geelhoed-Duijvestijn PH
    Neth J Med; 2007 Feb; 65(2):60-4. PubMed ID: 17379930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 based therapy for type 2 diabetes.
    Yu BS; Wang AR
    World J Pediatr; 2008 Feb; 4(1):8-13. PubMed ID: 18402245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.